Stephen D. Ferrone, CEO of Immunosyn, to Present at Flaherty Financial News/Wall Street Research Conference
January 18 2008 - 12:11PM
PR Newswire (US)
LA JOLLA, Calif., Jan. 18 /PRNewswire-FirstCall/ -- Stephen D.
Ferrone, President and CEO of Immunosyn Corporation (OTC:IMYN)
(BULLETIN BOARD: IMYN) , will present to a diverse group of
investors, portfolio managers and analysts at the Flaherty
Financial/Wall Street Research Small Cap Conference on January 22,
2008 at The Penn Club in New York City. A webcast of the
presentation will be available and archived for 60 days at
http://www.visualwebcaster.com/event.asp?=42359. "We are privileged
to present Immunosyn to the elite group of investors, industry
experts and analysts at the Flaherty Financial News/Wall Street
Research Small Cap Conference," says Ferrone. "This is a great
opportunity to increase market awareness for Immunosyn, to
articulate our vision and goals and to show the ways in which we
are moving closer to achieving them." Immunosyn's objectives,
overview and product information will be communicated to target
audiences at select conferences such as the Flaherty Financial/Wall
Street Research Small Cap Conference. Presentations will be made
which include market data, research information and milestones
achieved. As part of Immunosyn's presentation, Ferrone will focus
on the biopharmaceutical SF-1019, including information about the
steps being taken toward regulatory approvals and results of a
recent trial. About Flaherty Financial News Flaherty Financial News
is the publisher of totally-electronic coverage of the neglected
micro- and small-cap markets with Flaherty Financial News
Newsletter and Flaherty Special Situations. Both were recently
launched by the "legendary financial editor" Bob Flaherty, Editor
and Chairman of Flaherty Financial News Inc., and his son Brian,
who serves as President and Publisher. To opt in for future issues
please visit http://www.flahertyfinancialnews.com/ and log in.
About WallStreet Research WallStreet Research (WSR) is a prominent
research boutique led by Alan Stone, Managing Director of Alan
Stone & Company, LLC (ASC). The firm specializes in the micro-
and small- cap investment arena, seeking emerging growth companies
with strong management, unique or proprietary technology,
significant market potential, financial strength and outstanding
long-term earnings growth possibilities. WSR has offices in Los
Angeles, CA, Palm Beach, FL and New York City, NY. About Immunosyn
Corporation La Jolla, CA-headquartered Immunosyn Corporation
(IMYN.OTC.BB) plans to market and distribute life enhancing
therapeutics. Currently, the company has exclusive worldwide rights
from its largest shareholder, Argyll Biotechnologies, LLC, to
market, sell and distribute SF-1019, a compound that was developed
from extensive research into Biological Response Modifiers (BRMs).
Argyll Biotechnologies, LLC has initiated the process for
regulatory approval of SF-1019 in several countries and
preparations for clinical trials are underway in both the US and
Europe. Research suggests that SF-1019 has the potential to affect
a number of clinical conditions including complications from
Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic
ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS)
and neurological disorders such as Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic
Dystrophy Syndrome (RSD or RSDS). (For more information on
Immunosyn and SF-1019 go to http://www.immunosyn.com/) The above
news release contains forward-looking statements. These statements
are based on assumptions that management believes are reasonable
based on currently available information, and include statements
regarding the intent, belief or current expectations of the Company
and its management. Prospective investors are cautioned that any
such forward-looking statements are not guarantees of future
performance, and are subject to a wide range of business risks,
external factors and uncertainties. Actual results may differ
materially from those indicated by such forward-looking statements.
For additional information, please consult the Company's most
recent public filings and Annual Report on Form 10-K for its most
recent fiscal year. The Company assumes no obligation to update the
information contained in this press release, whether as a result of
new information, future events or otherwise. For further
information, contact: Bill Kraus/Lisa Baker/Devon Blaine The Blaine
Group 310/360-1499 310/360-1498 (FAX) DATASOURCE: Immunosyn
Corporation CONTACT: Bill Kraus or Lisa Baker or Devon Blaine of
The Blaine Group, +1-310-360-1499, fax, +1-310-360-1498, , for
Immunosyn Corporation Web site: http://www.immunosyn.com/
Copyright